Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis

Dermatologic Therapy

Volumn 29, Issue 5, 2016, Pages 358-363

  Rajabi, Omid ^a,b   Layegh, Pouran ^c   Hashemzadeh, Sara ^c   Khoddami, Mohsen ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

azithromycin; cutaneous leishmaniasis; liposome; treatment

Indexed keywords

AZITHROMYCIN; MEGLUMINE ANTIMONATE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DERMATOLOGIST; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; LIPOSOMAL DELIVERY; MAJOR CLINICAL STUDY; MALE; PAPULE; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN NODULE; SKIN PLAQUE; SKIN ULCER; TREATMENT RESPONSE;

EID: 84990176257     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12357     Document Type: Article

References (24)

1. Gaynor M, Mankin AS. Macrolide antibiotics: binding site, mechanism of action, resistance. Front Med Chem 2005; 2: 21–35.
2. Peters DH, Friedel HA, McTavish. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750–799.
3. Wildfeuer A, Haberreiter A. Intracellular activity of azithromycin against Mycobacterium avium complex in human macrophages. Arzneimittelforschung 1997; 47: 866–868.
4. Krolewiecki A, Leon S, Scott P, Abraham D. Activity of azithromycin against leishmania major in vitro and in vivo. Am J Trop Med Hyg 2002; 67: 273–277.
5. Sinagra A, Luna C, Abraham D, Iannella Mdel C, Riarte A, Krolewiecki AJ. The activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis in the golden hamster model. Rev Soc Bras Med Trop 2007; 40: 627–630.
6. Tanyuksel M, Levent BA, Araz E, Aybay C. Determination of intracellular efficacies of azithromycin against Leishmania major infection in human neutrophils in vitro. Cell Biochem Funct 2003; 21: 93–96.
7. Shahbazi F, Shahabi S, Kazemi B, Mohebali M, Abadi AR, Zare Z. Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. Parasitol Res 2008; 103: 1159–1162.
8. Kirby C, Gregoriadis G. Dehydretion–rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 1984; 2: 979–984.
9. Yu Z, Xiaoliang L, Yue C, Huifeng H, Na C, Xing T. Aspects of degradation kinetics of azithromycin in aqueous solution. Chromatographia 2009; 70: 67–73.
10. Mohammadzadeh M, Behnaz F, Golshan Z. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran. J Infect Public Health 2013; 6: 120–124.
11. Krolewiecki A, Scott P, Abraham D. The anti-Leishmania activity of azithromycin in an in-vitro model. Rev Soc Brasil Med Trop 1999; 32: 137.
12. de Oliveira-Silva F, de Morais-Teixeira E, Rabello A. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am J Trop Med Hyg 2008; 78: 745–749.
13. Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T. Efficacy of azithromycin versus systemic meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2007; 77: 99–101.
14. Silva-Vergara ML, Silva Lde A, Maneira FR, da Silva AG, Prata A. Azithromycin in the treatment of mucosal leishmaniasis. Rev Inst Med Trop Sao Paulo 2004; 46: 175–177.
15. Prata A, Silva-Vergara ML, Costa L, et al. Efficacy of Azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003; 36: 65–69.
16. Briones E, Colino CI, Lanao JM. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release 2008; 125: 210–227.
17. Sachetelli S, Khalil H, Chen T, Beaulac C, Senechal S, Lagace J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta 2000; 1463: 254–266.
18. Oh YK, Nix DE, Straubinger RM. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother 1995; 39: 2104–2111.
19. Khodami M. Topical liposomal Azithromycin in cutaneous leishmaniasis of animal model BALB/c mouse. Thesis of specialty in dermatology, Mashhad University of Medical Sciences, 2010.
20. Layegh P, Rajabi O, Jafari MR, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res 2011; 2011: 656523.
21. Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol 2007;56: 612–616.
22. Jaafari MR, Bavarsad N, Bazzaz BS, et al. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2009; 53: 2259–2265.
23. Carneiro G, Santos DC, Oliveira MC, et al. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 2010; 20: 16–23.
24. Momeni A, Rasoolian M, Momeni A, et al. Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis. J Liposom Res 2013; 23: 134–44.